Skip to main content

Table 3 Patients Using Liquid 16% Intramuscular Immune Serum Globulin*

From: Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens

    

Monthly Dose

No. of Infusions

Details per Infusion

Patient

Patient

Age

Weight

  

Per

Per

Dose

Volume

No. of

Duration

mL/kg/

No.

Name

(yr)

(kg)

(g)

(mg/kg)

Week

Month

(g)

(cc)

Sites

(h)

h/site

1

CK

1

10.0

3.2

320

--

2

1.6

10

1

2

0.500

2

PK

1

11.8

3.2

271

--

2

1.6

10

1

2

0.424

3

JK

3

18.1

8.0

440

1

5

1.6

10

1

2-3

0.221

4

AP

10

19.5

9.6

492

1†

6

1.6

10

1

2

0.256

5

ML

10

27.8

19.2

690

3

12

1.6

10

1

1.5

0.347

6

TS

10

34.0

19.2

556

3

12

1.6

10

1

2

0.147

7

EE

12

36.2

19.2

530

1

4

4.8

30

2

1.5

0.276

8

SJ

3

39.0

16.0

410

2-3

10

1.6

10

1

8 (sleep)

0.032

9

DJ

1

70.7

51

724

2

8

6.4

40

2

4-6

0.056

10

NB

51

77.0

.2

664

2

8

6.4

40

2

3

0.087

11

FW

50

88.6

51.2

558

3-4

15

3.2

20

3

3

0.250

12

NW

46

136.5

48.0

379

1

4

12.8

80

3

3

0.065

  1. *BayGam, unit dose of 1.6 g.
  2. †Once per week plus one extra infusion per month.
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us